您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Patritumab
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Patritumab
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:1262787-83-6
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议
50mg电议

产品名称
Human Anti-ERBB3 Recombinant Antibody
产品介绍
Patritumab (Human Anti-ERBB3 Recombinant Antibody) 是针对ERBB3的中和性单克隆抗体。Patritumab与 Cetuximab (HY-P9905) 具有协同作用,可有效抑制EGFRHER2HER3ERKAKT的磷酸化。Patritumab 也能诱导细胞凋亡 (apoptosis),也抑制胰腺、非小细胞肺癌和结直肠癌异种移植物肿瘤的生长。
生物活性

Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody toERBB3. Patritumab shows a synergy withCetuximab(HY-P9905), potently inhibits the phosphorylation ofEGFR,HER2,HER3,ERK, andAKT. Patritumab also induces cellapoptosisand suppresses the growth of pancreatic, non-small cell lungcancer, and colorectalcancerxenograft tumors[1].

体外研究
(In Vitro)

Patritumab targets to the extracellular domain (ECD) of HER3 and (10 μg/mL; 5 d) induces DiFi-HRG4 cells apoptosis[1].
Patritumab (10 μg/mL; 6 h) markedly inhibits the phosphorylation of HER3 and AKT, without affecting that of ERK, in DiFi-HRG4 cells[1].
Patritumab (10 μg/mL; 48 h) also induces the cleavage of PARP accompanied with both up-regulation of BIM and down-regulation of survivin expression[1].

Western Blot Analysis[1]

Cell Line:DiFi-HRG cells
Concentration:10 μg/mL
Incubation Time:6 hours
Result:Inhibited the phosphorylation of HER3 and AKT as well as down-regulated survivin expression.
体内研究
(In Vivo)

Patritumab (1 mg/mouse; i.p.; twice a week for 4 weeks) combines with 1 mg Cetuximab and restores Cetuximab sensitivity in DiFi-HRG tumor xenografts model in mice[1].
Heregulin produced by colorectal cancer tumors harboring wild-type KRAS induces Cetuximab resistance, and that combination therapy with cetuximab and patritumab overcomes such resistance in vivo[1].

Animal Model:Female athymic nude mice (BALB/c; 5-6 weeks old) with DiFi-Mock1 or DiFi-HRG4 (s.c.)[1]
Dosage:1 mg/body
Administration:Intraperitoneal injection; twice a week for 4 weeks
Result:Individual Patritumab treatment had little effect on the growth of tumors formed by either cell line.
Combination of Cetuximab and Patritumab induced substantial regression of DiFi-HRG4 xenografts.
性状

Liquid

CAS 号

1262787-83-6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.